Clinical Trial

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Study acronym: ECLIPSE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population.
Protocol Amendment History 31 amendments
This ClinicalTrials.gov record has been amended 31 times since 2019-10-21; most recent amendment 2026-05-11.
Status change: Completed → Active, Not Recruiting 2026-05-11
Status change: Active, Not Recruiting → Completed 2025-08-06
Status change: Recruiting → Active, Not Recruiting 2024-04-26
Trial Details
NCT Number NCT04136002
Lead Sponsor Guardant Health, Inc.
Collaborators: Premier Research
Conditions Colorectal Cancer
Enrollment 44,467 participants
Start Date 2019-10-08
Primary Completion 2024-03-20 (estimated)
Study Completion 2027-08-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-14